Apmonia Therapeutics
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $7.6Mattributed |
|---|---|
| Latest round | grant, $2.7M, 2024-09-01attributed |
| Founded | 2019 |
| Headquarters | Reims, France |
| Industry | biotech |
| Stage | unknown |
| Website | apmonia-therapeutics.com |
Apmonia Therapeutics develops peptide-based therapies targeting the tumor microenvironment, with lead candidate AP-01 (TAX2) blocking TSP-1 binding to CD47. The Reims-based biotech serves patients with glioblastoma, ovarian, colorectal, and pancreatic cancer. Its peptide approach offers an alternative to other CD47 blockers while modulating.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-09-01 | grant | $2.7M | undisclosed |
Detected tech stack
PHP 8.4, WordPress 6.9.4, Twenty Seventeen, Yoast SEO 27.6, Google Analytics, Google Tag Manager, jQuery Migrate 3.4.1, imagesLoaded 5.0.0, Elementor 4.0.8, DoubleClick Floodlight, Contact Form 7 6.1.6, CookieYes 3.4.2
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $7.6M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | apmonia-therapeutics.com, read 2026-05-02 |
| Description | self-reported | apmonia-therapeutics.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.